Virtual screening analysis and in-vitro xanthine oxidase inhibitory activity of some commercially available flavonoids

Iranian Journal of Pharmaceutical Research

Volumn 12, Issue 3, 2013, Pages 317-323

  Umamaheswari, Muthuswamy ^a   Madeswaran, Arumugam ^a   Asokkumar, Kuppusamy ^a  

^a India)   (India)

Author keywords

Binding energy; Enzyme kinetics; Flavonoids; Gout; Xanthine oxidase

Indexed keywords

ALLOPURINOL; DAIDZEIN; EPIGALLOCATECHIN; FLAVONOID; GLYCITEIN; MYRICETIN; NARINGENIN; XANTHINE OXIDASE;

ARTICLE; DRUG SCREENING; ENZYME BINDING; ENZYME INHIBITION; ENZYME KINETICS; GOUT; IC 50; ULTRAVIOLET SPECTROPHOTOMETRY;

EID: 84883788709     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Reichel A. The role of blood-brain barrier studies in the pharmaceutical industry. Curr. Drug Metab. (2006) 7: 183-203.
2. Seeliger D and Groot LB. Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J. Comput. Aided Mol. Des. (2010) 24: 417-22.
3. Lin CN, Kuo SH, Chung MI, Ko FN and Teng CM. A new favone C-glycoside and antiplatelet and vasorelaxing favones from Gentiana arisanensis. J. Nat. Prod. (1997) 60: 851-53.
4. Hirashima A and Huang H. Homology modeling, agonist binding site identifcation, and docking in octopamine receptor of Periplaneta americana. Comput. Biol. Chem. (2008) 32: 185-90.
5. Powers R. Advances in nuclear magnetic resonance for drug discovery. Expert Opin. Drug Disc. (2009) 4: 1077-98.
6. Breda A, Basso LA, Santos DS and Walter F. Virtual screening of drugs: score functions, docking, and drug design. Curr. Comp. Aided Drug Des. (2008) 4: 265-72.
7. Morris MG, Goodsell SD, Halliday SR, Huey R, Hart EW, Belew KR and Olson JA. Automated docking using a lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. (1998) 19: 1639-62.
8. Symons CRM, Taiwo AF and Petersen LR. Electron addition to xanthine oxidase. An electron spins resonance study of the effects of ionizing radiation. J. Chem. Soc. (1989) 85: 4063-74.
9. Zarepour M, Kaspari K, Stagge S, Rethmeier R, Mendel RR and Bittner F. Xanthine dehydrogenase AtXDH1 from Arabidopsis thaliana is a potent producer of superoxide anions via its NADH oxidase activity. Plant Mol. Biol. (2010) 72: 301-10.
10. Egwim EC, Vanchi MA and Egwin PO. Comparison of xanthine oxidase activities in cow and goat milks. Biokemistri (2005) 17: 1-6.
11. Borges F, Fernandes E and Roleira F. Progress towards the discovery of xanthine oxidase inhibitors. Curr. Med. Chem. (2002) 9: 195-217.
12. Umamaheswari M, Asokkumar K, Sivashanmugam AT, Remyaraju A, Subhadradevi V and Ravi TK. In-vitro xanthine oxidase inhibitory activity of the fractions of Erythrina stricta Roxb. J. Ethnopharmacol. (2009) 124: 646-8.
13. Lio M, Moriyama A, Matsumoto Y, Takaki N and Fukumoto M. Inhibition of xanthine oxidase by favonoids. Agric. Biol. Chem. (1985) 49: 2173-6.
14. Karrasch T, Kim JS, Jang IB and Jobin C. The favonoid luteolin worsens chemical-induced colitis in NF-κBEGFP transgenic mice through blockade of NF- κB-dependent protective molecules. PLoS ONE (2007) 2: 596-8.
15. Venkatachalam CM, Jiang X, Oldfeld T and Waldman M. LigandFit: A novel method for the shape-directed rapid docking of ligands to protein active sites. J. Mol. Graph. Model (2003) 21: 289-307.
16. Sherman DH, Li S, Yermaliskaya VL, Kim Y, Smith AJ, Waterman RM and Podust ML. The structural basis for substrate anchoring, active site selectivity, and product formation by P450 PikC from Streptomyces venezuelae. J. Biol. Chem. (2006) 281: 26289-97.
17. Yasutake Y, Imoto N, Fujii T, Arisawa A and Tamura T. Crystal structure of cytochrome P450 MoxA from Nonomuraea recticatena (CYP105). Biochem. Biophys. Res. Commun. (2007) 361: 876-82.
18. Sugimoto H, Shinkyo R, Hayashi K, Yoneda S, Yamada M, Kamakura M, Ikushiro S, Shiro Y and Sakaki T. Crystal structure of CYP105A1 (P450SU-1) in complex with 1alpha,25-dihydroxyvitamin D3. Biochem. (2008) 47: 4017-27.
19. Sahgal G, Ramanathan S, Sasidharan S, Mordi MN, Ismail S and Mansor SM. In-vitro antioxidant and xanthine oxidase inhibitory activities of methanolic Swietenia mahagoni seed extracts. Molecules (2009) 14: 4476-85.
20. Meda NTR, Lamien MA, Kiendrebeogo M, Lamien CE, Coulibaly AY, Mjllogo RJ and Nacoulma OG. In-vitro antioxidant, xanthine oxidase and acetylcholinesterase inhibitory activities of Balanites aegyptiaca (L.) Del. (Balanitaceae). Pak. J. Biol. Sci. (2010) 13: 362-8.
21. Werns SW, Grum CM, Ventura A, Hahn RA, Ho PP, Towner RD, Fantone JC, Schork MA and Lucchesi BR. Xanthine oxidase inhibition does not limit canine infarct size. Circulation (1991) 83: 995-1005.
22. Chen Q, Groote R, Schonherr H and Vancso GJ. Probing single enzyme kinetics in real-time. J. Chem. Soc. (2009) 38: 2671-83.
23. Henderson JF. Steady-state enzyme kinetics with high-affnity substrates or inhibitors. A statistical treatment of dose-response curves. J. Biochem. (1973) 135: 101-7.
24. Pacher P, Nivorozhkin A and Szabo C. Therapeutic effect of xanthine oxidase inhibitors renaissance half a century after the discovery of allopurinol. Pharmacol. Rev. (2006) 58: 87-114.
25. Unno T, Sugimoto A and Kakuda T. Xanthine oxidase inhibitors from the leaves of Lagerstroemia speciosa (L.) Pers. J. Ethnopharmacol. (2004) 93: 391-5.
26. Priyatno LHA, Sukandar EY, Ibrahim S and Adnyna IK. Xanthine oxidase inhibitory activity of terpenoid and pyrrole compound isolated from Snake fruit (Salacca edulis Reinw.) cv. Bongkok. J. App. Sci. (2007) 7: 3127-30.
27. Nguyen MTT, Awale S, Tezuka Y, Shi L, Tran LQ, Watanabe H and Kadota H. Xanthine oxidase inhibitors from the heart wood of Vietnamese Caesalpinia sappan. Chem. Pharm. Bull. (2005) 53: 984-8.
28. Hsu C. Antioxidant activity of extracts from Polygonum aviculare L. Biol. Res. (2006) 39: 281-8.